CELF1 was reported to promote proliferation, migration, and invasion of CRC cells in vitro and in vivo through upregulating ETS2 and induced resistance to oxaliplatin (Wang et al., 2020). This evidence concerns the gene CELF1 and colorectal carcinoma.